Overview

Effect of Sevoflurane and Propofol on Hepato-splanchnic Pressure and Flow During Hepatobiliary Surgery

Status:
Completed
Trial end date:
2018-12-04
Target enrollment:
0
Participant gender:
All
Summary
Blood loss in hepatobiliary surgery is correlated with an increase in postoperative complications (e.g. transfusion related lung injury and tumor recurrence) and reduced longterm survival. To reduce morbidity and mortality in hepatobiliary surgery, modulation of the hepato-splanchnic blood flow and pressure is used. In liver surgery pharmacological modulations are widely used to prevent blood loss. For pharmacological modulation central venous pressure is commonly used to reduce the pressure in the inferior vena cava, however little is known about pharmacological effect on blood flow in the hepatic artery and portal vein. The modulation of the hepato-splanchnic blood flow can also play an important role, not only for prevention of blood loss but also for survival of the organs (e.g. ischemic injury due to low flow). Volatile anesthetics induce a dose-dependent reduction of the hepato-splanchninc blood flow. Propofol however, increases hepatic blood flow when compared with volatile anesthetics. Pharmacological modulation of hepato-splanchnic bloodflow with anesthetics such as sevoflurane or propofol can play an important role in modulation of ischemia/reperfusion injury and survival of organs. The aim of the study is to determine and to compare the effect of sevoflurane versus propofol on hepatosplanchnic pressure and hepato-splanchnic blood flow during hepatobiliary surgery.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University Hospital, Ghent
Treatments:
Propofol
Sevoflurane
Criteria
Inclusion Criteria:

- Adult ≥ 18 years (Female or Male)

- ASA I - II - III

- Able to comprehend, sign and date the written informed consent document to participate
in the clinical trial.

- Scheduled for hepato-biliary surgery.

Exclusion Criteria:

- Allergy for the medication

- Renal insufficiency (SCr > 2 mg/dl)

- Severe heart failure (EF < 25%)

- Hemodynamic instable patients

- Arterial fibrillation

- Sepsis

- BMI > 40

- Severe coagulopathy (INR > 2)

- Thrombocytopenia (< 80 x 10³ /µL)

- History of severe postoperative nausea & vomiting